ストックスクリーナーアプリを入手
52.02
6.27%
3.07
Halozyme Therapeutics Inc (HALO) 最新ニュース
J&J, Halozyme cut at Leerink on price control risk for combo products - MSN
Halozyme downgraded at Morgan Stanley on price control risk - MSN
Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq
Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance
Leerink Partners Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq
Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World
Morgan Stanley Downgrades Halozyme Therapeutics (BMV:HALO) - Nasdaq
Halozyme Therapeutics (HALO) Downgraded by Morgan Stanley | HALO Stock News - GuruFocus
Halozyme, J&J slide as analyst cuts rating on CMS draft guidance - Yahoo Finance
Halozyme (HALO) Downgraded Amid Medicare Price Negotiation Conce - GuruFocus
Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ) - Seeking Alpha
Halozyme Therapeutics downgraded by Morgan Stanley with a new price target - Quantisnow
Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday - Yahoo Finance
Halozyme stock holds $78 target despite Medicare concerns By Investing.com - Investing.com Canada
Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concer - GuruFocus
Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concerns | HALO Stock News - GuruFocus
Halozyme stock holds $78 target despite Medicare concerns - Investing.com
Morgan Stanley cuts Halozyme stock rating, lowers target By Investing.com - Investing.com Nigeria
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - MSN
Halozyme at BofA Securities Conference: Strategic Growth Insights By Investing.com - Investing.com Nigeria
Transcript : Halozyme Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04 - marketscreener.com
Evercore ISI maintains Outperform on Halozyme amid CMS draft By Investing.com - Investing.com Canada
Halozyme at BofA Securities Conference: Strategic Growth Insights - Investing.com Australia
Halozyme stock rating cut to Underperform at Leerink Partners By Investing.com - Investing.com Nigeria
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News - Investor's Business Daily
Evercore ISI maintains Outperform on Halozyme amid CMS draft - Investing.com
Halozyme Shares Fall After Leerink Partners Downgrade - marketscreener.com
Crude Oil Gains 3%; US Inflation Eases In April - Benzinga
Halozyme Therapeutics (HALO) Downgraded Amid Medicare Negotiatio - GuruFocus
Halozyme (HALO) Stock Downgraded Amid Concerns Over CMS Guidance - GuruFocus
J&J stock Halozyme stock cut at Leerink Partners (JNJ:NYSE) - Seeking Alpha
Halozyme stock rating cut to Underperform at Leerink Partners - Investing.com
Halozyme (HALO) Faces Downgrade Amid Potential Revenue Risks | H - GuruFocus
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Leerink Partners Downgrades Halozyme Therapeutics to Underperform From Market Perform, Price Target is $47 - marketscreener.com
Halozyme shares tumble on downgrade and CMS draft guidance By Investing.com - Investing.com Canada
Halozyme shares tumble on downgrade and CMS draft guidance - Investing.com
Halozyme Therapeutics downgraded by Leerink Partners with a new price target - Quantisnow
Is Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now? - Insider Monkey
(HALO) Technical Data - news.stocktradersdaily.com
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat (NASDAQ:HALO) - Seeking Alpha
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Cut to Hold at Benchmark - Defense World
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Benzinga
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates - MSN
Halozyme sees strong Q1 2025 growth, raises 2025 revenue guidance to $1.2B-$1.28B - MSN
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View - MSN
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - NewsBreak: Local News & Alerts
Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Halozyme Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 1-Year High After Better-Than-Expected Earnings - Defense World
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):